pI: 8.8081 |
Length (AA): 334 |
MW (Da): 37873 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 7
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_127441)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G62430 | phosphatidate cytidylyltransferase |
Arabidopsis thaliana | AT4G26770 | phosphatidate cytidylyltransferase |
Arabidopsis thaliana | AT4G22340 | cytidinediphosphate diacylglycerol synthase 2 |
Babesia bovis | BBOV_II005070 | cytidine diphosphate-diacylglycerol synthase, putative |
Brugia malayi | Bm1_36290 | Putative phosphatidate cytidylyltransferase |
Candida albicans | CaO19.8866 | CDP-diacylglycerol synthase |
Candida albicans | CaO19.1279 | CDP-diacylglycerol synthase |
Caenorhabditis elegans | CELE_C33H5.18 | Protein C33H5.18, isoform A |
Cryptosporidium hominis | Chro.70059 | cytidine diphosphate-diacylglycerol synthase |
Cryptosporidium parvum | cgd7_450 | putative cytidine diphosphate-diacylglycerol synthase; integral membrane protein with 7 or more transmembrane domains |
Dictyostelium discoideum | DDB_G0269742 | CDP-diacylglycerol synthase |
Drosophila melanogaster | Dmel_CG7962 | CDP diglyceride synthetase |
Echinococcus granulosus | EgrG_001128500 | phosphatidate cytidylyltransferase |
Echinococcus multilocularis | EmuJ_001128500 | phosphatidate cytidylyltransferase |
Giardia lamblia | GL50803_16906 | Phosphatidate cytidylyltransferase |
Homo sapiens | ENSG00000101290 | CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 |
Homo sapiens | ENSG00000163624 | CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 |
Leishmania braziliensis | LbrM.26.1640 | cdp-diacylglycerol synthetase-like protein |
Leishmania donovani | LdBPK_261600.1 | CDP-DAG synthase, putative |
Leishmania infantum | LinJ.26.1600 | cdp-diacylglycerol synthetase-like protein |
Leishmania major | LmjF.26.1620 | cdp-diacylglycerol synthetase-like protein |
Leishmania mexicana | LmxM.26.1620 | cdp-diacylglycerol synthetase-like protein |
Loa Loa (eye worm) | LOAG_03064 | phosphatidate cytidylyltransferase |
Mus musculus | ENSMUSG00000029330 | CDP-diacylglycerol synthase 1 |
Mus musculus | ENSMUSG00000058793 | CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 |
Neospora caninum | NCLIV_023660 | Phosphatidate cytidylyltransferase (EC 2.7.7.41), related |
Oryza sativa | 4325310 | Os01g0758400 |
Oryza sativa | 4348326 | Os10g0327300 |
Plasmodium berghei | PBANKA_1032600 | cytidine diphosphate-diacylglycerol synthase, putative |
Plasmodium falciparum | PF3D7_1409900 | cytidine diphosphate-diacylglycerol synthase |
Plasmodium knowlesi | PKNH_1348400 | cytidine diphosphate-diacylglycerol synthase |
Plasmodium vivax | PVX_085955 | cytidine diphosphate-diacylglycerol synthase, putative |
Plasmodium yoelii | PY01816 | phosphatidate cytidylyltransferase, putative |
Saccharomyces cerevisiae | YBR029C | phosphatidate cytidylyltransferase |
Schistosoma japonicum | Sjp_0001040 | ko:K00981 phosphatidate cytidylyltransferase [EC2.7.7.41], putative |
Schistosoma mansoni | Smp_144030 | phosphatidate cytidylyltransferase |
Schmidtea mediterranea | mk4.000129.13 | Probable phosphatidate cytidylyltransferase |
Trypanosoma brucei gambiense | Tbg972.7.100 | phosphatidate cytidylyltransferase |
Trypanosoma brucei | Tb927.7.220 | CDP-DAG synthase |
Trypanosoma cruzi | TcCLB.511237.40 | CDP-DAG synthase, putative |
Toxoplasma gondii | TGME49_281980 | phosphatidate cytidylyltransferase |
Theileria parva | TP04_0048 | phosphatidate cytidylyltransferase, putative |
Trichomonas vaginalis | TVAG_430160 | phosphatidate cytidylyltransferase, putative |
Trichomonas vaginalis | TVAG_491120 | phosphatidate cytidylyltransferase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.220 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.220 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.220 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.7.220 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_C33H5.18 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_C33H5.18 | Caenorhabditis elegans | larval lethal | wormbase |
CELE_C33H5.18 | Caenorhabditis elegans | sterile | wormbase |
YBR029C | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_1032600 | Plasmodium berghei | Essential | plasmo |
TGME49_281980 | Toxoplasma gondii | Probably essential | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.